Sr. Director, ADC Drug-Linker Synthetic Process Development at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceutical, Biotechnology, HealthcareIndustries

Requirements

Ph.D. in synthetic organic chemistry or relevant scientific discipline with >8 years of experience
B.S. or M.S. with 15+ years of demonstrated equivalent experience in a related field of expertise
Proven leadership experience managing small molecule CMC development programs
Proven leadership experience leading scientific teams through all stages of development from discovery

Responsibilities

Lead and oversee CMC process development activities for novel payloads and drug-linkers within ADC programs, ensuring alignment with overall program goals
Collaborate closely with Discovery teams to ensure manufacturability and facilitate smooth transition from early research to CMC development
Develop scalable, robust, and reproducible processes for payload linker synthesis, enabling seamless technology transfer from development labs to GMP manufacturing
Build and strengthen internal capabilities by developing team expertise, infrastructure, and technologies related to payload linker process development
Stay current on emerging technologies and scientific advancements in ADC linker and payload chemistry to maintain competitive edge
Champion a strong safety culture in all laboratory activities, ensuring proper handling, containment, and risk assessment practices for highly potent compounds
Provide technical guidance and career development support to team members, including goal setting, performance evaluations, and skills enhancement
Manage external collaborations with vendors and CDMOs specializing in linker and payload synthesis and process development
Ensure compliance with regulatory guidelines and support filing activities for INDs, BLAs, and other regulatory submissions

Skills

Key technologies and capabilities for this role

ADCDrug-Linker SynthesisSynthetic ChemistryProcess DevelopmentBioconjugatesMonoclonal AntibodiesPayload Linker DevelopmentSmall Molecule Chemistry

Questions & Answers

Common questions about this position

What is the employment type for this position?

This is a full-time position.

Is this role remote or does it require working from a specific location?

This information is not specified in the job description.

What are the key responsibilities for this Senior Director role?

The role involves leading CMC process development for novel payloads and drug-linkers in ADC programs, collaborating with Discovery teams, developing scalable processes for payload linker synthesis, building internal capabilities, and staying current on emerging technologies.

What is the work environment like at Eli Lilly?

The role thrives in a collaborative and fast-paced work environment within a multidisciplinary organization focused on biologic therapeutics.

What makes a strong candidate for this Sr. Director position?

A strong candidate is highly experienced and strategic in payload linker development, with a strong commitment to employee development, and the ability to lead in a collaborative, fast-paced environment at the small molecule-biologics interface.

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free